Alimera Sciences, Inc. ALIM
Set alert
5.54 +5.54 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 301.29M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 29.16
- Beta
- 1.25
- Short ratio
- 1.93
- Inst. own
- 86.54%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Oct 24, 2024
- 50-d avg
- 5.56
- 200-d avg
- 4.23
- 1y target
- 5.67
2Y chart
Events in this range
- May 15, 2023Rating: HC Wainwright & Co. · Buy → Buy
- May 18, 2023Rating: HC Wainwright & Co. · Buy → Buy
- May 24, 2023Rating: HC Wainwright & Co. · Buy → Buy
- Aug 10, 2023Earnings: —; estimate 0.06; surprise —%
- Oct 26, 2023Earnings: —; estimate -0.41; surprise —%
- Mar 7, 2024Earnings: —; estimate 0.02; surprise —%
- May 14, 2024Earnings: —; estimate -0.04; surprise —%
- Aug 6, 2024Earnings: —; estimate -0.03; surprise —%
Signals (94)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Sep 10, 2024 | 2 years ago |
| SMA: Bearish | Sep 3, 2024 | 2 years ago |
| RSI: Overbought | Aug 23, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 15, 2024 | 2 years ago |
| SMA: Bullish | Jun 24, 2024 | 2 years ago |
| SMA: Bullish | Jun 24, 2024 | 2 years ago |
| RSI: Overbought | Jun 24, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 12, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 10, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 7, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 6, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 4, 2024 | 2 years ago |
| MACD: Sell Signal | May 14, 2024 | 2 years ago |
| SMA: Bearish | May 13, 2024 | 2 years ago |
| SMA: Bullish | May 10, 2024 | 2 years ago |
| SMA: Bearish | May 9, 2024 | 2 years ago |
| SMA: Bearish | May 7, 2024 | 2 years ago |
| SMA: Bullish | May 6, 2024 | 2 years ago |
| SMA: Bullish | May 3, 2024 | 2 years ago |
| SMA: Bearish | May 1, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 30, 2024 | 2 years ago |
| SMA: Bullish | Apr 29, 2024 | 2 years ago |
| SMA: Bearish | Apr 25, 2024 | 2 years ago |
| SMA: Bullish | Apr 22, 2024 | 2 years ago |
| SMA: Bearish | Apr 18, 2024 | 2 years ago |
| SMA: Bearish | Apr 12, 2024 | 2 years ago |
| SMA: Bullish | Apr 11, 2024 | 2 years ago |
| SMA: Bearish | Apr 10, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 27, 2024 | 2 years ago |
| SMA: Bullish | Mar 12, 2024 | 2 years ago |
| SMA: Bearish | Mar 11, 2024 | 2 years ago |
| SMA: Bullish | Mar 5, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 1, 2024 | 2 years ago |
| SMA: Bullish | Feb 22, 2024 | 2 years ago |
| SMA: Bearish | Feb 21, 2024 | 2 years ago |
| SMA: Bearish | Feb 13, 2024 | 2 years ago |
| SMA: Bullish | Feb 1, 2024 | 2 years ago |
| SMA: Bearish | Jan 31, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 5, 2024 | 2 years ago |
| MACD: Buy Signal | Dec 29, 2023 | 2 years ago |
| RSI: Overbought | Dec 29, 2023 | 2 years ago |
| MACD: Sell Signal | Dec 27, 2023 | 2 years ago |
| RSI: Overbought | Dec 15, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 5, 2023 | 2 years ago |
| SMA: Bullish | Dec 1, 2023 | 2 years ago |
| SMA: Bearish | Nov 29, 2023 | 2 years ago |
| MACD: Sell Signal | Nov 29, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 22, 2023 | 2 years ago |
| SMA: Bullish | Nov 17, 2023 | 2 years ago |
| SMA: Bearish | Nov 16, 2023 | 2 years ago |
| MACD: Sell Signal | Nov 16, 2023 | 2 years ago |
| SMA: Bullish | Oct 30, 2023 | 3 years ago |
| SMA: Bearish | Oct 27, 2023 | 3 years ago |
| SMA: Bullish | Oct 26, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 20, 2023 | 3 years ago |
| SMA: Bullish | Oct 16, 2023 | 3 years ago |
| SMA: Bearish | Oct 13, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 11, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 5, 2023 | 3 years ago |
| SMA: Bearish | Sep 15, 2023 | 3 years ago |
| SMA: Bullish | Sep 14, 2023 | 3 years ago |
| SMA: Bearish | Sep 13, 2023 | 3 years ago |
| SMA: Bullish | Sep 7, 2023 | 3 years ago |
| SMA: Bearish | Sep 5, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 25, 2023 | 3 years ago |
| MACD: Buy Signal | Aug 22, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 21, 2023 | 3 years ago |
| MACD: Buy Signal | Aug 15, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 25, 2023 | 3 years ago |
| RSI: Overbought | Jul 19, 2023 | 3 years ago |
| RSI: Overbought | Jul 14, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 10, 2023 | 3 years ago |
| RSI: Overbought | Jul 10, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 15, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 13, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 9, 2023 | 3 years ago |
| MACD: Buy Signal | May 17, 2023 | 3 years ago |
| SMA: Bullish | May 16, 2023 | 3 years ago |
| SMA: Bearish | May 5, 2023 | 3 years ago |
| SMA: Bullish | May 4, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 27, 2023 | 3 years ago |
| SMA: Bullish | Apr 19, 2023 | 3 years ago |
| SMA: Bearish | Apr 18, 2023 | 3 years ago |
| SMA: Bullish | Apr 14, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 27, 2023 | 3 years ago |
| RSI: Oversold | Mar 22, 2023 | 3 years ago |
| RSI: Oversold | Mar 15, 2023 | 3 years ago |
| RSI: Oversold | Mar 1, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 9, 2023 | 3 years ago |
| SMA: Bearish | Feb 3, 2023 | 3 years ago |
| SMA: Bullish | Feb 2, 2023 | 3 years ago |
| MACD: Buy Signal | Dec 27, 2022 | 3 years ago |
| RSI: Oversold | Nov 25, 2022 | 3 years ago |
Key statistics
- Market cap
- 301.29M
- Enterprise value
- 362.91M
- Trailing P/E
- 5.28
- Forward P/E
- 29.16
- PEG ratio
- 0.00
- Price / sales
- 3.02
- Price / book
- 7.49
- EPS (TTM)
- 1.05
- Beta
- 1.25
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -14.74%
- Revenue (TTM)
- 99.68M
- Revenue growth
- 54.00%
- Free cash flow
- -2.18M
- Total cash
- 10.83M
- Total debt
- 72.45M
- Return on equity
- -34.57%
- Shares outstanding
- 54.38M
- Short % of float
- 3.03%
- 50-day average
- 5.56
- 200-day average
- 4.23
Analyst view
Consensus: hold
Hold
Price target (mean) 5.67 +2.3% upside
Now 5.54
- Target (low)
- 5.50
- Target (mean)
- 5.67
- Target (high)
- 6.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Oct 24, 2024
Expected Oct 24, 2024. Consensus EPS estimate -0.01.
Financials — quick view
ALIM Revenue — quarterly 27.00M
ALIM Net income — quarterly -3.31M
ALIM EPS — quarterly -0.06
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 24, 2024 | Sep 1, 2024 | -0.01 | — | — | — |
| Aug 6, 2024 | Jun 1, 2024 | -0.03 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.04 | — | — | — |
| Mar 7, 2024 | Dec 1, 2023 | 0.02 | — | — | — |
| Oct 26, 2023 | Sep 1, 2023 | -0.41 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.06 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 11, 2023 | Alliance Global Partners | up | Neutral | Buy |
| May 24, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 18, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| May 15, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 2, 2023 | HC Wainwright & Co. | reit | — | Buy |
About Alimera Sciences, Inc.
Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- alimerasciences.com
News
- ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
- ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences
- Alimera Sciences (ALIM) Soars 6.6%: Is Further Upside Left in the Stock?
- ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences
- Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
- Alimera Sciences Reports Second Quarter 2024 Results
- ALIM ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc.
- SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM
- SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. – ALIM
- SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM
Your note
Sign in to keep a note on ALIM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ASHMAN PHILIP | Chief Operating Officer | Stock Award(Grant) | Mar 23, 2023 | 133,315 |
| CALIGAN PARTNERS L,P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 13, 2023 | 0 |
| EISWIRTH RICHARD S JR | Chief Executive Officer | Stock Award(Grant) | Oct 1, 2023 | 722,518 |
| HOLLAND DAVID R | Officer | Stock Award(Grant) | Mar 23, 2023 | 108,880 |
| JONES JOHN PHILIP | Chief Financial Officer | Stock Award(Grant) | Oct 30, 2022 | 32,185 |
| MORGAN ADAM | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 14, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Velan Capital Investment Management LP | 18.86% | 1,659,654 | 4.85M | Jun 29, 2023 |
| Morgan Stanley | 7.57% | 666,246 | 1.95M | Jun 29, 2023 |
| Caligan Partners, LP | 5.44% | 478,777 | 1.40M | Jun 29, 2023 |
| Healthcare of Ontario Pension Plan Trust Fund | 2.84% | 250,000 | 730.00K | Jun 29, 2023 |
| Vanguard Group Inc | 1.61% | 141,393 | 412.87K | Jun 29, 2023 |
| Renaissance Technologies, LLC | 1.47% | 129,716 | 378.77K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.99% | 87,148 | 254.47K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 0.62% | 54,245 | 158.40K | Jun 29, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.23% | 20,000 | 58.40K | Jun 29, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 0.21% | 18,300 | 53.44K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.16% | 13,786 | 37.91K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.15% | 13,038 | 35.85K | May 30, 2023 |